Autophilic antibodies

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S133100, C424S141100, C424S146100, C424S155100, C435S069600, C503S223000, C503S223000, C503S223000, C503S223000

Reexamination Certificate

active

07569674

ABSTRACT:
Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.

REFERENCES:
patent: 5191066 (1993-03-01), Bieniarz et al.
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5276170 (1994-01-01), Kirk et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5563046 (1996-10-01), Mascarenhas et al.
patent: 5596081 (1997-01-01), Haley et al.
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5763733 (1998-06-01), Whitlow et al.
patent: 5800991 (1998-09-01), Haley et al.
patent: 5807746 (1998-09-01), Lin et al.
patent: 5811265 (1998-09-01), Quertermous et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 5969109 (1999-10-01), Bona et al.
patent: 6008319 (1999-12-01), Epstein et al.
patent: 6043339 (2000-03-01), Lin et al.
patent: 6117656 (2000-09-01), Seed
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6207804 (2001-03-01), Huston et al.
patent: 6218160 (2001-04-01), Duan
patent: 6224870 (2001-05-01), Segal
patent: 6228603 (2001-05-01), Reed et al.
patent: 6235667 (2001-05-01), Paloschi et al.
patent: 6238667 (2001-05-01), Kohler
patent: 6248558 (2001-06-01), Lin et al.
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6316003 (2001-11-01), Frankel et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6426413 (2002-07-01), Wannamaker et al.
patent: 6432680 (2002-08-01), Lin et al.
patent: 6482586 (2002-11-01), Arab et al.
patent: 6566338 (2003-05-01), Weber et al.
patent: 6596693 (2003-07-01), Keana et al.
patent: 6620782 (2003-09-01), Cai et al.
patent: 6716410 (2004-04-01), Witztum et al.
patent: 6762045 (2004-07-01), Krebs et al.
patent: 6780605 (2004-08-01), Frostegard et al.
patent: 6821274 (2004-11-01), McHale et al.
patent: 7041459 (2006-05-01), Singh et al.
patent: 2002/0143142 (2002-10-01), Lin et al.
patent: 2003/0103984 (2003-06-01), Kohler
patent: 2003/0143226 (2003-07-01), Kobayashi et al.
patent: 2003/0148265 (2003-08-01), Brooks et al.
patent: 2004/0185039 (2004-09-01), Kohler et al.
patent: 2005/0033033 (2005-02-01), Kohler et al.
patent: 2006/0233790 (2006-10-01), Futaki et al.
patent: WO-9617625 (1996-06-01), None
patent: WO-9620219 (1996-07-01), None
patent: WO-9914244 (1999-03-01), None
patent: WO-0160866 (2001-08-01), None
patent: WO02097041 (2002-12-01), None
patent: WO-03080115 (2003-10-01), None
patent: WO-2006119291 (2006-11-01), None
Lederman et al. Molecular Immunology 28:1171-1181, 1991.
Li et al. Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Nakamura et al. Cancer Research, 54(6):1511-1516, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
Ghetie, M. et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells,”PNAS USA, (1997) 94; pp. 7509-7514.
Kang, C-Y, et al. “Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide,”Science, (1988) 240:1034-1036.
Kang, C-Y, et al, “Immunoglobulin with complementary paratope and idiotope,”J. Exp. Med. (1986) 163: 787.
Kaveri, S., et al., “Antibodies of different specificities are self-binding: implication for antibody diversity,”Mol. Immunol., (1991) 2: 733-78.
Kaveri, S., et al., “Self-binding antibodies (autobodies) form specific complexes in solution,”J. Immunol. (1990) 145: 2533-2538.
Kohler, H., et al., “Superantibody activities: new players in innate and adaptive immune responses,”Immun. Today, (1998) 19:221-227.
Kohler, H., “Superantibodies: synergy of innate and acquired immunity,”Appl. Biochem. Biotechnol., (2000) 83: 1-9.
Lin, Y., et al, “Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence,” J.Biol Chem, (1995) 270: 14255-14258.
Muller, S., et al., “TransMabs: cell-penetrating antibodies, the next generation,”Expert Opin. Biol. Ther., (2005) 5: 237-241.
Rojas, M., et al., “Genetic engineering of proteins with cell membrane permeability,”Nat. Biotechnol., (1998) 16: 370-375.
Zhao, Y., et al., “Chemical engineering of cell penetrating antibodies,”J. Immun. Methods, (2001) 254: 137-145.
Zhao, Y., et al., “Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers,”J. Immunotherapy, (2002) 25(5): 1-9.
Zhao, Y., et al., “Enhanced Anti-B-cell Tumor Effects with Anti-CD20 Superantibody,”J. Immunotherapy, (2002) 25: 57-62.
Binder, M., F. Otto, R. Mertelsmann, H. Veelken, and M. Trepel. “The epitope recognized by rituximab.” Blood 2006, vol. 108, No. 6, pp. 1975-1978.
Braendstrup, P., O.W. Bjerrum, O.J. Nielsen, B.A. Jensen, N.T. Clausen, P.B. Hansen, I. Andersen, K. Schmidt, T.M. Andersen, N.A. Peterslund, H.S. Birgens, T. Plesner, B.B. Pedersen, and H.C. Hasselbalch. “Rituximab Chimeric Anti-CD20 Monoclonal Antibody Treatment for Adult Refractory Idiopathic Thrombocytopenic Purpura.” American Journal of Hematology 2005, vol. 78, pp. 275-280.
Burton, C., R. Kaczmarski, R. Jan-Mohamed. “Interstitial Pneumonitis Related to Rituximab Therapy.” The New England Journal of Medicine 2003, vol. 348, No. 26, pp. 2690-2691.
Edwards, J.C.W., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw. “Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis.” The New England Journal of Medicine 2004, vol. 350, No. 25, pp. 2572-2581.
Pandey, R.N., L.E. Davis, B. Anderson, and P.F. Hollenberg. “Photochemical linking of primary aromatic amines to carrier proteins to elicit antibody response against the amine haptens.” Journal of Immunological Methods 1986, vol. 94, pp. 237-246.
Lambris, J.D., V.S. Ganu, S. Hirani, and H.J. Muller-Eberhard. “Mapping the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.” Proceedings of the National Academy of Sciences USA 1985, vol. 82, pp. 4235-4239.
Frankel, A.E. “Antibody-Toxin Hybrids: A Clinical Review of Their Use.” Journal of Biological Response Modifiers 1985, vol. 4, pp. 437-446.
Chaddock, J.A., L.M. Roberts, B. Jungnickel, and J. Michael Lord. “A hydrophobic region of ricin a chain which may have a role in membrane translocation can function as an efficient noncleaved signal peptide.” Biochemical and Biophysical Research Communications 1995, vol. 217, No. 1, pp. 68-73.
Morris, K.N. and I.G. Wool. “Analysis of the contribution of an amphiphilic α-helix to the structure and to the function of ricin A chain.” Proceedings of the National Academy of Sciences USA 1994, vol. 91, pp. 7530-7533.
Kohler, H., G. Pavlinkova, K. Rajagopalan, H-T. Wang, S. Chatterjee, and B. Haley. “Specific photoaffinity-labeling locus on antibodies: use for chelation, protein conjungation and gene delivery.” Journal of Cellular Biochemistry Supplement, Abstract T029, No. 18D, 1994, pp. 189.
Pavlinkova, G., K. Rajagopalan, S. Muller, A. Chavan, G. Sievert, D. Lou, C. O'Toole , B. Haley, and H. Kohler. “Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers.” Journal of Immunological Methods 1997, vol. 201, pp. 77-88.
Miles, E.W. and R.S. Phillips. “Photoinactivation and Photoaffinity Labeling of Tryptophan Synthase

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Autophilic antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Autophilic antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Autophilic antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4070422

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.